AOD-9604 vs Syn-Coll
Side-by-side comparison of key properties, dosing, and research.
- Summary
- AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
- Syn-Coll is a palmitoylated tripeptide (Palmitoyl Tripeptide-5) that mimics thrombospondin-1 to activate TGF-beta, the primary growth factor driving collagen synthesis in the dermis. It is one of the most mechanistically direct collagen-stimulating peptides in cosmetic formulations.
- Half-Life
- 30-45 minutes injectable; longer with nasal spray formulation
- Extended (lipid depot in stratum corneum)
- Admin Route
- SubQ, Intranasal, Oral
- Topical
- Research
- —
- —
- Typical Dose
- 300-600 mcg
- 0.005-0.05% in formulation
- Frequency
- Once daily
- Once or twice daily
- Key Benefits
- Selective fat loss without anabolic side effects
- No effect on blood glucose or insulin resistance
- Improved bioavailability over Fragment 176-191
- GRAS (Generally Recognized As Safe) status in Australia
- Potential cartilage repair and anti-inflammatory properties
- Does not suppress natural GH production
- Directly activates TGF-beta for potent collagen synthesis stimulation
- Increases dermal thickness and firmness
- Reduces depth of wrinkles and fine lines
- Improves skin elasticity
- Clinically validated in collagen induction studies
- Complementary to retinoids or vitamin C
- Side Effects
- Localized injection site reactions
- Headache (rare)
- Hypoglycemia risk in combination with insulin (very rare)
- Generally well-tolerated
- Rare mild irritation at high concentrations
- Possible sensitivity in individuals with inflammatory skin conditions
- Stacks With
- —
- —